Document is current

Article History

Accepted: 27 March 2025

First Online: 16 April 2025

Declarations

:

: The Section Editors for the topical collection Opioids are Brian Fuehrlein and Mark Gold. Please note that Section Editor Mark Gold was not involved in the editorial process of this article as he is a co-author.

: M.S.G. has served as the chief scientific officer for ADAPT and advised for Emergent. S.L.W. has served as a paid scientific advisor/consultant for entities with products in development or marketed products related to opioid use disorder, including Astra Zeneca, Cerevel, Reacx, Kinnoxis, Braeburn Pharmaceuticals and Opiant. E.W.B. serves as an expert witness in litigation, is a non-compensated board member of Coagulo and Torus Biosystems and receives product liability consulting fees from International Herbal and Plant Alliance. B.M., C.C., and J.P. have nothing to disclose. The conduct of the RESPIRE Expert Forum and the development of this manuscript were funded by Indivior. Indivior manufactures and markets IN nalmefene (OPVEE ® ) in the United States.

: Insights shared during the RESPIRE Expert Forum are based on personal opinion and experiences only and are not representative of each author’s respective organization or place of employment. A modest honorarium at fair market value was offered to each of the RESPIRE Expert Forum participants; however, no additional honoraria were provided for drafting and reviewing the manuscript. Two additional experts contributed to the Forum but not to the drafting and reviewing of the manuscript.